

# *aap* Implantate AG Corporate Presentation

## **German Equity Forum 2015** Frankfurt am Main, November 24, 2015

Bruke Seyoum Alemu, CEO Marek Hahn, CFO



# Safe Harbor Statement



Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions.

# aap Company Overview



- German based international MedTech company
- Listed in Frankfurt, Germany, Prime standard (XETRA: AAQ.DE)
- 2014: Sales EUR 30.6 million\*, EBITDA (norm.) EUR 1.4 million\*\*
- Operating with two Centres of Excellence

Center of Excellence Trauma, Berlin		Center of Excellence Biomaterials, Dieburg
<ul> <li>Comprehensive plates &amp; screws portfolio</li> <li>Silver coating technology</li> <li>R&amp;D and manufacturing in-house</li> </ul>	Technologies, Products and Services	<ul> <li>Comprehensive portfolio of bone cements and accessories as well as biomaterials</li> <li>R&amp;D and manufacturing in-house</li> <li>Service value chain for third parties: R&amp;D → approval &amp; registration → supply</li> </ul>
<ul> <li>B2C: direct sales force in DACH, international distributors in RoW</li> <li><i>aap</i> label</li> </ul>	Business Model	<ul><li>B2B: OEM and contract manufacturing</li><li>Private label</li></ul>
<ul> <li>Hospitals and Distributors worldwide with focus on Europe, BRICS, SMIT, US</li> </ul>	Customer Base	Global orthopedic companies
LOCATER Decking Compression Technology von aap		Image: Stryker*   Stryker* Stryker* TORNIER * INTEGRA DePuy Synthes DePuy Synthes Medtronic * Medtronic * Mathys * Smith&nephew *

\*Figures relate solely to continued operations

\*\*EBITDA excluding one-off effects of equity disposal, one-off costs in connection with strategic measures and project proceeds and costs incurred in connection with them

# aap Trauma – LOQTEQ<sup>®</sup> Product Line



#### Concept Protected by several global patents sliding locking One Step One Hole One Screw Screw Head Plate ←Two-Part combined → fracture line taper compression of connection fracture in final (bone moving) position

## Application

Mainstream trauma, lower & upper extremities



## **Competitive Environment**

#### Entirely benchmarked against the market leader




# aap Trauma – LOQTEQ<sup>®</sup> Product Line



## Portfolio


#### **Comprehensive and procedure focused**



## **Growth Track Record**

Driven by BRICS, SMIT and Europe

#### LOQTEQ<sup>®</sup> sales



## Value Proposition

- Genuine alternative to the gold standard with new and additional features
- Clinical and economical advantages:
  - Optimum instrumentation and efficient procedures,
  - Excellent anatomical fit,
  - Strong clinical evidence of no cold-welding,
  - Competitive price

# aap Trauma – LOQTEQ® Development



0.4

1.8


5.0

# aap Silver Coating – Value-based innovation

### **Unmet Need**

Infection prevention for medical devices

#### Surgical Site Infection (SSI)




Biofilm formed on an TiAl6V4 implant surface *S. epidermidis* ATCC 35984

### Technology

PEO – Plasma ElectroOxydation
In-house developed
IP protected
Cost-effective Coating technique
Very short coating time
Comparably low investment
Easily up-scalable
Applicable on all relevant geometries

#### **Innovative Solution**



### **First Application expected 2016**



# *aap* Silver Coating – Benchmarking\*


	аар	Market Leader 1	Market Leader 2
Antibacterial agent	micro-Ag / nano-Ag	AgNO <sub>3</sub>	micro-Ag / nano-Ag
Coating principle	Single step: Electrochemical (PEO)	4-step in 2 solutions: Electrochemical (acidic anodization) & dipping	Multi-step: vacuum deposition
Antibacterial efficacy	+	+	+
Biocompatibility	+	-	+
Silver directly effective	+	+	-
Coating stability	+	+	+
Process simplicity	+	+/-	-
Cost-effectiveness	+	+	_
Prevention efficiency	5,5 μg/cm <sup>2</sup> LOG4 & <b>NO</b> cytotox	50 μg/cm <sup>2</sup> LOG4 <b>BUT</b> cytotox 6 μg/cm <sup>2</sup> No cytotox <b>BUT</b> only LOG2	Full silver layer by PVD
Coating time	< 10 min	~ 4 h	30 min to 1 h
Additional characteristics	Up-scaling & shorter coating time achievable	Inhomogeneous distribution of Ag	Complicated coating process

\* Based on available information (publications, patents, conferences' lectures, posters, press releases etc.)

# aap Silver Coating – Regulatory Path


## **Results delivered**

#### Comprehensive animal trials accomplished to a large extent



## **Regulatory Path**

Short term targeted CE- and FDA-clearance



# aap's Aspiration and Imperatives




#### MISSION

Making trauma treatment better and cost-effective

#### VISION

Become a leading European trauma company

#### STRATEGIC IMPERATIVES



# Implementation of Strategic Imperatives Progress in 2015

Products Customers **Accelerating Value-based Innovation Enhancing Market Access** LOQTEQ<sup>®</sup>: portfolio extension toward full range main Headwind in BRICS and SMIT countries stream trauma (>90% indication coverage) > Experienced sales leadership team for DACH, North LOQTEQ<sup>®</sup>: portfolio development for lower and upper America and RoW put in place for the next LOQTEQ® extremities growth phase > Silver coating technology: approval-relevant animal > USA: growth driver from 2016 onward, several studies accomplished to a large extent distribution contracts signed; first sales **Getting focussed** on Trauma > aap Biomaterials divestment in process **Optimizing Operational Supplementing Organic** Efficiency **Growth with Acquisition** 

- Continuous market screening; M&A rationales: complementary portfolio, geographical expansion, cost synergies
  - High acquisition multipliers in recent transactions remain challenging

Distribution

visible effects impacting overall cost reduction

Production cost optimization measures on track with

Significant increase in production

output of anatomical plates per guarter

Services

Cost

# Outlook 2015




### • Updated Outlook 2015:

- Sales: EUR 27.5 million EUR 31.5 million
- EBITDA: EUR -1.5 million EUR 1.0 million
- Transformation of *aap* Implantate AG into a **focused trauma company** remains core objective of our strategic direction

# Implementation of Strategic Imperatives

### **Getting focused on Trauma**

Focus on core business								
	2008	2009	2010	2011	2012	2013	2014	2015
Dental	+							
Analytics	+	+						
Medical Aesthetics	+	+						
Recon	+	+	+	+	+			
Contract Manufacturing	+	+	+	+	+	+		
Biomaterials	+	+	+	+	+	+	+	(+)
Trauma	+	+	+	+	+	+	+	+



Transformation from diversified to focused MedTech company

## 2008 - 2015

## 2016 and beyond

# aap – Sum of the Parts




#### *aap* Trauma

- Strong sales growth in the first three years after launch 2012-2014; CAGR 2011-2014: 174%
- Strong IP, comprehensive portfolio for mainstream trauma as well as extremities (foot & ankle)
- Sales 2014: EUR 12.2m
- Valuation: Median EV/Sales of 4-6 in recent global transactions of pure trauma companies

#### aap Silver

- Technology addresses unmet need of the industry (infection prevention)
- Strong IP, platform technology with a wide range of applications
- Cost-effective coating technology with high efficacy and good biocompatibility
- Valuation: huge potential due to platform technology for wide range of applications: orthopaedics, cardiovascular, dental, instruments etc.





# The New *aap* – 2016 and beyond

## **Completely transformed business**

<b>DIFFERENTIATIO</b> <i>aap</i> with a unique positio and opportunity for futur growth	n <i>aap</i> with multiple drivers for	<b>OUR GOALS</b> <i>aap</i> with a sound strategy to create value
Focused on most attractive higher growth segments of orthopedics: trauma and extremities	launches leading to	<ul> <li>Sales CAGR &gt;20%</li> <li>EBITDA margins &gt;20% in 3 to 4 years</li> </ul>
Strong IP portfolio for all I platform technologies	key International expansion with focus on Europe, US, BRICS and SMIT	• Attractive valuation as pure and fast-growing trauma player with strong IP
LOQTEQ and Silver Coatin technologies address unn needs of the industry	- I Uncoming antipacterial silver	<ul> <li>Substantial hidden reserve due to broad application of silver coating technology outside trauma</li> </ul>

## Contact





*aap* Implantate AG Lorenzweg 5 12099 Berlin

Fabian Franke Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de Website: www.aap.de IR-app:





# Appendix



## Highlights FY/2014 – Financial Figures (in EUR million)

	FY/2014*	FY/2013	Change
Sales	30.6	28.6	7%
Trauma	12.2	9.6	27%
of which LOQTEQ®	8.2	5.0	63%
Biomaterials	16.4	15.0	10%
Projects	1.2	2.8	-58%
Other	0.8	1.2	-31%

	FY/2014*	FY/2013	Change
EBITDA	2.3	5.1	-55%
of which projects	0.8	4.4	-82%
of which one-off effects	0.1	0.3	-67%
EBITDA normalised**	1.4	0.4	> +100%
EBIT	-0.1	0.8	< -100%

\*Figures relate solely to continued operations, with previous year's figures adjusted accordingly

\*\*EBITDA excluding one-off effects of equity disposal, one-off costs in connection with strategic measures and project proceeds and costs incurred in connection with them

	12/31/2014	12/31/2013	Change
Total Assets	57.9	65.2	-11%
Intangible Assets	15.2	14.5	5%
Intangible Assets ratio	26%	22%	-
Equity ratio	79%	72%	-
Net cash (FY/2013: net debt)	+7.7	-3.4	> +100%
DCR rolling (last four quarters)	2.0	0.8	> +100%
ICR rolling (last four quarters)	16.8	22.7	-39%



## Highlights 9M/2015 – Financial Figures (in EUR million)

	9M/2015*	9M/2014	Change
Sales	22.0	22.1	0%
Trauma	8.5	8.4	1%
of which LOQTEQ®	5.2	5.3	-2%
Biomaterials	13.0	12.7	2%
Projects	0.2	0.3	-25%
Other	0.3	0.7	-59%

	9M/2015*	9M/2014	Change
EBITDA	-0.3	2.4	< -100%
of which projects	0.2	0.0	> +100%
of which one-off effects	-0.8	1.0	< -100%
EBITDA normalised**	0.3	1.4	< -77%
EBIT	-2.3	0.8	< -100%

\*Figures relate solely to continued operations, with previous year's figures adjusted accordingly


\*\*EBITDA excluding one-off effects of equity disposal, one-off costs in connection with strategic measures and project proceeds and costs incurred in connection with them

	09/30/2015	12/31/2014	Change
Total Assets	61.5	57.9	6%
Intangible Assets	15.4	15.2	1%
Intangible Assets ratio	25%	26%	-
Equity ratio	71%	79%	-
Net cash	+3.1	+7.7	-60%
DCR rolling (last four quarters)	-17.8	2.0	< -100%
ICR rolling (last four quarters)	-2.6	16.8	< -100%

# **Shareholder structure**



- Growing interest in *aap*'s value driving strategy is also reflected in new shareholders:
  - December 2013: Taaleritehdas ArvoRein Equity Fund, Finland
  - March 2014: Ennismore Fund Management Limited, UK
  - April 2014: Fidelity Funds SICAV, Luxembourg
  - January 2015: Ratio Capital Management B.V., Netherlands
- Market Cap amounts to approx. EUR 46 million\*\*



#### Capital Stock: 30,832,156 million

- Ratio Capital Management B.V., Netherlands
- Jürgen W. Krebs, Switzerland
- Noes Beheer B.V., Netherlands
- Taaleritehdas ArvoRein Equity Fund, Finland
- Deepblue Holding AG, Switzerland
- Elocin B.V., Netherlands
- Ennismore Fund Management Limited, United Kingdom
- Fidelity Funds SICAV, Luxembourg
- Free Float\*

\* According to own calculations \*\* As of 11/20/2015